2026 Global: Cholangiocarcinoma Market-Competitive Review (2032) report
Description
The 2026 Global: Cholangiocarcinoma Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cholangiocarcinoma market by geography and historical trend. The scope of the report extends to sizing of the cholangiocarcinoma market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Merck Sharp & Dohme (Merck) is a major cholangiocarcinoma player focused on immuno-oncology combinations and targeted agents, leveraging its broad oncology portfolio and clinical trial programs to pursue improved outcomes in biliary tract cancers. Incyte Corporation is a leading specialist in targeted FGFR inhibition, marketed pemigatinib (Pemazyre®) for FGFR2-fusion cholangiocarcinoma and remains a central commercial and clinical force in FGFR-directed therapy for the disease. AstraZeneca has significant presence through immunotherapy strategies—most notably durvalumab in combination regimens for biliary tract cancers—and invests in trials that integrate checkpoint inhibitors with chemotherapy and targeted agents to expand indications in cholangiocarcinoma. Eisai contributes important tyrosine kinase inhibitor experience, with lenvatinib used in liver and biliary cancers and ongoing combination studies pairing TKIs with immunotherapies to enhance efficacy in advanced cholangiocarcinoma.
Roche (including Genentech/Loxo affiliates) participates via targeted and combination regimens, developing precision approaches and biomarker-driven trials, and has been active in testing immune‑oncology agents with chemotherapy backbones in biliary tract malignancies. QED Therapeutics (BridgeBio/QED) focuses on FGFR inhibitors such as infigratinib, positioning the company as a competitive targeted‑therapy developer for FGFR2‑altered cholangiocarcinoma with active clinical programs in earlier and later lines. RedHill Biopharma concentrates on niche and repurposed compounds with clinical-stage assets in biliary cancers and maintains development programs specifically addressing cholangiocarcinoma indications, contributing to non‑chemotherapy treatment options in the space. TransThera Sciences is an emerging biotech in the cholangiocarcinoma pipeline with small‑molecule kinase inhibitors (e.g., tinengotinib) targeting molecular subsets of intrahepatic cholangiocarcinoma and advancing candidates through Phase I/II studies.
Bristol‑Myers Squibb (BMS) leverages its immunotherapy franchise to pursue checkpoint inhibitor‑based strategies in biliary tract cancer trials and collaborative combinations aimed at improving survival endpoints in refractory and first‑line settings. Taiho Oncology (and partner organizations) operates in the cholangiocarcinoma and intrahepatic cholangiocarcinoma markets through cytotoxic and targeted agents, development partnerships, and regionally focused clinical programs that address unmet needs in Asian and global patient populations. Each of these ten companies contributes distinct capabilities—commercialized targeted drugs (Incyte, QED), large‑scale immuno‑oncology platforms and combination trial capacity (Merck, AstraZeneca, Roche, BMS), kinase/TKI expertise and regional development (Eisai, Taiho), and focused pipeline innovation from smaller biotechs (RedHill, TransThera)—together shaping a market driven by molecular stratification, combination regimens, and expanding clinical trial activity for cholangiocarcinoma treatment advancement.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cholangiocarcinoma market by geography and historical trend. The scope of the report extends to sizing of the cholangiocarcinoma market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Merck Sharp & Dohme (Merck) is a major cholangiocarcinoma player focused on immuno-oncology combinations and targeted agents, leveraging its broad oncology portfolio and clinical trial programs to pursue improved outcomes in biliary tract cancers. Incyte Corporation is a leading specialist in targeted FGFR inhibition, marketed pemigatinib (Pemazyre®) for FGFR2-fusion cholangiocarcinoma and remains a central commercial and clinical force in FGFR-directed therapy for the disease. AstraZeneca has significant presence through immunotherapy strategies—most notably durvalumab in combination regimens for biliary tract cancers—and invests in trials that integrate checkpoint inhibitors with chemotherapy and targeted agents to expand indications in cholangiocarcinoma. Eisai contributes important tyrosine kinase inhibitor experience, with lenvatinib used in liver and biliary cancers and ongoing combination studies pairing TKIs with immunotherapies to enhance efficacy in advanced cholangiocarcinoma.
Roche (including Genentech/Loxo affiliates) participates via targeted and combination regimens, developing precision approaches and biomarker-driven trials, and has been active in testing immune‑oncology agents with chemotherapy backbones in biliary tract malignancies. QED Therapeutics (BridgeBio/QED) focuses on FGFR inhibitors such as infigratinib, positioning the company as a competitive targeted‑therapy developer for FGFR2‑altered cholangiocarcinoma with active clinical programs in earlier and later lines. RedHill Biopharma concentrates on niche and repurposed compounds with clinical-stage assets in biliary cancers and maintains development programs specifically addressing cholangiocarcinoma indications, contributing to non‑chemotherapy treatment options in the space. TransThera Sciences is an emerging biotech in the cholangiocarcinoma pipeline with small‑molecule kinase inhibitors (e.g., tinengotinib) targeting molecular subsets of intrahepatic cholangiocarcinoma and advancing candidates through Phase I/II studies.
Bristol‑Myers Squibb (BMS) leverages its immunotherapy franchise to pursue checkpoint inhibitor‑based strategies in biliary tract cancer trials and collaborative combinations aimed at improving survival endpoints in refractory and first‑line settings. Taiho Oncology (and partner organizations) operates in the cholangiocarcinoma and intrahepatic cholangiocarcinoma markets through cytotoxic and targeted agents, development partnerships, and regionally focused clinical programs that address unmet needs in Asian and global patient populations. Each of these ten companies contributes distinct capabilities—commercialized targeted drugs (Incyte, QED), large‑scale immuno‑oncology platforms and combination trial capacity (Merck, AstraZeneca, Roche, BMS), kinase/TKI expertise and regional development (Eisai, Taiho), and focused pipeline innovation from smaller biotechs (RedHill, TransThera)—together shaping a market driven by molecular stratification, combination regimens, and expanding clinical trial activity for cholangiocarcinoma treatment advancement.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
